Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Kafrelsheikh University: Clinical Trials & FDA Approval Profile

Kafrelsheikh University (Global / Institutional) sponsors 51 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 11 active protocols (5 recruiting now), 17 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)185 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Kafrelsheikh University
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)51
Active Pipeline (Recruiting Now)11 (5)
Completed vs Stopped Early17 / 0 (0.0%)
Median Closed Actual Enrollment185 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Kafrelsheikh University Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI